Perspectives of Photodynamic Therapy for Skin Diseases

Photodynamic therapy (PDT) is largely an experimental modality for the treatment of neoplastic and selected nonneoplastic diseases. This therapeutic procedure, through a cascade of events, leads to cell killing. In the past few years, dermatology has taken advantage of PDT for the treatment of skin cancer and other skin diseases. The skin has considerable attributes over many other organs for the application of PDT. These include the accessibility to all three PDT essential requirements; the drug (photosensitizing agent), visible light and oxygen. The major benefit of experimental PDT in dermatology is the ability to assess the clinical response visually and the relative ease in obtaining biopsies for precise biochemical and histological analysis. Currently, PDT has received approval worldwide for the ablation of various tumor types. In the United States, the Food and Drug Administration has approved PDT for the treatment of advanced esophageal cancer and selected patients with lung cancer. Clinical trials, employing several types of photosensitizers for PDT, are ongoing for a variety of dermatological lesions. This review summarizes current knowledge of PDT in dermatology and highlights future perspectives of this modality for effective management of skin diseases.

[1]  Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors. , 1996, Experimental eye research.

[2]  C. Gomer,et al.  ACUTE SKIN RESPONSE IN ALBINO MICE FOLLOWING PORPHYRIN PHOTOSENSITIZATION UNDER OXIC AND ANOXIC CONDITIONS , 1984, Photochemistry and photobiology.

[3]  R. Anderson,et al.  Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. , 1995, Archives of dermatology.

[4]  P. Speight,et al.  Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid , 1993, The Lancet.

[5]  A. J. MacRobert,et al.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. , 1993, British Journal of Cancer.

[6]  Merrill A. Biel,et al.  Photodynamic therapy and the treatment of malignancies of the head and neck , 1995, Photonics West.

[7]  M. Waner,et al.  Photodynamic Therapy for Multiple Skin Cancers , 1988, Plastic and reconstructive surgery.

[8]  J Moan,et al.  5‐Aminolevulinic acid‐based photodynamic therapy , 1997, Cancer.

[9]  J. Sessler,et al.  Lutetium Texaphyrin (PCI‐0123): A Near‐Infrared, Water‐Soluble Photosensitizer , 1996, Photochemistry and photobiology.

[10]  H. Hönigsmann,et al.  Photodynamic therapy of epithelial skin tumours using delta‐aminolaevulinic acid and desferrioxamine , 1995, The British journal of dermatology.

[11]  M F Mafee,et al.  Photodynamic therapy in the treatment of squamous cell carcinoma of the head and neck. , 1990, Archives of otolaryngology--head & neck surgery.

[12]  C. Elmets,et al.  PHOTODYNAMIC THERAPY OF CHEMICALLY‐ AND ULTRAVIOLET B RADIATION‐INDUCED MURINE SKIN PAPILLOMAS BY CHLOROALUMINUM PHTHALOCYANINE TETRASULFONATE , 1992, Photochemistry and photobiology.

[13]  Harvey Lui,et al.  Photodynamic therapy of malignant skin tumors with Benzoporphyrin derivative-monoacid ring A (BPD-MA): preliminary observations , 1993, Photonics West - Lasers and Applications in Science and Engineering.

[14]  J. Moan,et al.  On the diffusion length of singlet oxygen in cells and tissues , 1990 .

[15]  B. Allison,et al.  Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. , 1994, British Journal of Cancer.

[16]  M W Berns,et al.  Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. , 1985, Cancer research.

[17]  R. Mohan,et al.  Apoptosis is an Early Event During Phthalocyanine Photodynamic Therapy‐Induced Ablation of Chemically Induced Squamous Papillomas in Mouse Skin , 1996, Photochemistry and photobiology.

[18]  Richard A. Miller,et al.  Influence of drug and light regimens in determining PDT efficacy with lutetium texaphyrin , 1996, Photonics West.

[19]  C. Gomer.  PRECLINICAL EXAMINATION OF FIRST and SECOND GENERATION PHOTOSENSITIZERS USED IN PHOTODYNAMIC THERAPY , 1991, Photochemistry and photobiology.

[20]  T. Dougherty.  Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XI , 1994 .

[21]  Q. Peng,et al.  5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. , 1997, Cancer.

[22]  D. Visscher,et al.  Photodynamic Therapy for Treatment of AIDS-Related Oral Kaposi's Sarcoma , 1990, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[23]  T J Dougherty,et al.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. , 1976, Cancer research.

[24]  E G Hahn,et al.  Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. , 1995, Gastrointestinal Endoscopy.

[25]  P. Calzavara-Pinton,et al.  Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. , 1995, Journal of photochemistry and photobiology. B, Biology.

[26]  J. Reguła,et al.  Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study. , 1995, Neoplasma.

[27]  B. Steinberg,et al.  Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. , 1992, Archives of otolaryngology--head & neck surgery.

[28]  A Gorchein,et al.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. , 1995, Gut.

[29]  D. Separovic,et al.  Ceramide generation in response to photodynamic treatment of L5178Y mouse lymphoma cells. , 1997, Cancer research.

[30]  Hasan Mukhtar,et al.  Phthalocyanine Photodynamic Therapy: Disparate Effects of Pharmacologic Inhibitors on Cutaneous Photosensitivity and on Tumor Regression , 1997, Photochemistry and photobiology.

[31]  J. Kennedy,et al.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.

[32]  R. Agarwal,et al.  Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Hill,et al.  Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture , 1995, Melanoma research.

[34]  M Landthaler,et al.  Topical photodynamic therapy in dermatology. , 1996, Journal of photochemistry and photobiology. B, Biology.

[35]  B. Ortel,et al.  Perspectives in cutaneous photodynamic sensitization. , 1996, Journal of photochemistry and photobiology. B, Biology.

[36]  E. Ben-hur,et al.  Photodynamic Treatment of Red Blood Cell Concentrates For Virus Inactivation Enhances Red Blood Cell Aggregation: Protection with Antioxidants , 1997, Photochemistry and photobiology.

[37]  T. Dougherty.  Photodynamic therapy. , 1993, Photochemistry and photobiology.

[38]  C J Gomer,et al.  Properties and applications of photodynamic therapy. , 1989, Radiation research.

[39]  C. Foote.  DEFINITION OF TYPE I and TYPE II PHOTOSENSITIZED OXIDATION , 1991, Photochemistry and photobiology.

[40]  S. Gupta,et al.  Involvement of nitric oxide during phthalocyanine (Pc4) photodynamic therapy-mediated apoptosis. , 1998, Cancer research.

[41]  Q. Peng,et al.  PHOTOSENSITIZING EFFICIENCIES, TUMOR‐ and CELLULAR UPTAKE OF DIFFERENT PHOTOSENSITIZING DRUGS RELEVANT FOR PHOTODYNAMIC THERAPY OF CANCER , 1987, Photochemistry and photobiology.

[42]  G. Stables,et al.  The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. , 1996, The Journal of investigative dermatology.

[43]  Daniel R. Doiron,et al.  SnET2: clinical update , 1996, Photonics West.

[44]  Valery I. Chissov,et al.  Photodynamic therapy (PDT) of malignant tumors by photosensitzer photosens: results of 45 clinical cases , 1996, European Conference on Biomedical Optics.

[45]  T. Dougherty,et al.  HOW DOES PHOTODYNAMIC THERAPY WORK? , 1992, Photochemistry and photobiology.

[46]  B. Tromberg,et al.  In vivo TUMOR OXYGEN TENSION MEASUREMENTS FOR THE EVALUATION OF THE EFFICIENCY OF PHOTODYNAMIC THERAPY , 1990, Photochemistry and photobiology.

[47]  M. E. Kenney,et al.  REDISTRIBUTION AND VIRUS INACTIVATION EFFICACY OF A SILICON PHTHALOCYANINE IN RED BLOOD CELL CONCENTRATES AS A FUNCTION OF DELIVERY VEHICLE , 1995, Photochemistry and photobiology.

[48]  J. McCaughan,et al.  Hematoporphyrin‐Derivative and Photoradiation Therapy of Malignant Tumors , 1983, Lasers in surgery and medicine.

[49]  D. V. Ash,et al.  Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. , 1994, British Journal of Cancer.

[50]  H Lui,et al.  Current status of photodynamic therapy in dermatology. , 1997, Dermatologic clinics.

[51]  H Lui,et al.  Photodynamic therapy in dermatology: recent developments. , 1993, Dermatologic clinics.

[52]  H Kerl,et al.  Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? , 1993, Journal of the American Academy of Dermatology.

[53]  Maria G. Galpern,et al.  First clinical results with a new drug for PDT , 1995, Other Conferences.

[54]  R. Pottier,et al.  On the role of protoporphyrin IX photoproducts in photodynamic therapy. , 1995, Journal of photochemistry and photobiology. B, Biology.

[55]  K Svanberg,et al.  Photodynamic therapy of non‐melanoma malignant tumours of the skin using topical δ‐amino levulinic acid sensitization and laser irradiation , 1994, The British journal of dermatology.

[56]  T. Ruzicka,et al.  Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses , 1997, Photodermatology, photoimmunology & photomedicine.

[57]  P. Vaupel,et al.  PO2 distribution in tumor tissue of DS-carcinosarcoma. , 1974, Oncology.

[58]  J Moan,et al.  PHOTOCHEMOTHERAPY OF CANCER: EXPERIMENTAL RESEARCH , 1992, Photochemistry and photobiology.

[59]  G. Weinstein,et al.  Development of a topical hematoporphyrin derivative formulation: characterization of photosensitizing effects in vivo. , 1983, The Journal of investigative dermatology.

[60]  Harald B. Steen,et al.  Photodynamic therapy with 5-aminoolevulinic acid-induced porphyrins and DMSO/EDTA for basal cell carcinoma , 1994, Other Conferences.

[61]  F. Cairnduff,et al.  Photodynamic therapy of primary skin cancer: a review. , 1995, British journal of plastic surgery.

[62]  Konradin Metze,et al.  Enhancement of photodynamic therapy due to hyperbaric hyperoxia: an experimental study of Walker 256 tumors in rats , 1997, Photonics West - Biomedical Optics.

[63]  Michele T. Cooper,et al.  Photodynamic therapy for the treatment of basal cell carcinoma. , 1992, Archives of dermatology.

[64]  Tumor oxygen tension during photodynamic therapy. , 1990, Journal of photochemistry and photobiology. B, Biology.

[65]  J. McCaughan.  Photodynamic therapy of skin and esophageal cancers. , 1990, Cancer investigation.

[66]  M. E. Kenney,et al.  A Comparative Analysis of Silicon Phthalocyanine Photosensitizers for in vivo Photodynamic Therapy of RIF‐1 Tumors in C3H Mice , 1998, Photochemistry and photobiology.

[67]  M. Waner,et al.  Squamous cell carcinoma of the lower lip involving a large cutaneous surface. Photodynamic therapy as an alternative therapy. , 1990, Archives of dermatology.